Maneo (Tramadol Hydrochloride)

Tramadol Hydrochloride is used to treat pain conditions that require opioid analgesia.

• Acute postoperative pain: provides effective relief following surgical procedures.
• Chronic musculoskeletal pain: helps manage persistent pain from conditions such as osteoarthritis.
• Cancer‑related pain: offers moderate analgesia for patients with tumor‑associated discomfort.

• Tramadol Hydrochloride exerts analgesic activity primarily through weak agonism of the μ‑opioid receptor, reducing neuronal excitability. In addition, it inhibits the reuptake of serotonin and norepinephrine, enhancing descending inhibitory pain pathways. This dual mechanism results in decreased perception of painful stimuli without the potency of stronger opioids. The drug is metabolized in the liver to O‑desmethyltramadol, a metabolite with higher affinity for the μ‑opioid receptor, contributing further to its analgesic effect.

Tramadol Hydrochloride may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate feeling of queasiness that may resolve with continued therapy.
• Dizziness: transient light‑headedness or loss of balance, especially on standing.
• Constipation: reduced bowel movements that can be managed with diet or laxatives.
• Headache: mild to moderate head pain that may improve with analgesics.

Serious or Rare Side Effects

• Seizures: risk of convulsive episodes, higher in patients with pre‑existing seizure disorders.
• Respiratory depression: slowed breathing that can be life‑threatening, requiring immediate medical attention.
• Serotonin syndrome: symptoms such as agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents.

When prescribing Tramadol Hydrochloride, clinicians should observe several safety considerations to minimize risk.

• Assess pain severity: confirm that opioid therapy is appropriate for the patient’s level of pain.
• Evaluate renal and hepatic function: dose adjustments may be needed in impairment.
• Review concomitant CNS depressants: avoid additive sedation or respiratory effects.
• Monitor for signs of dependence or abuse: educate patients on proper use.
• Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Tramadol Hydrochloride interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use can precipitate serotonin syndrome.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): may enhance respiratory depression and sedation.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increase risk of serotonin syndrome.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise tramadol plasma levels, potentially intensifying effects.
• Anticoagulants (e.g., warfarin): may increase bleeding tendency.